Although further analyses are needed to confirm these findings and to define sensitivity and specificity, our data suggest an ability of the presented PSMA ligand to detect low differentiated PC lesions as well (low PSA levels despite multiple metastases and high initial GSC, e.g. patients 12 and 15). This evidence concerns the gene FOLH1 and pachyonychia congenita.